Hugel, Inc. (KOSDAQ:145020)

Market Cap	2.61T -29.2%
Revenue (ttm)	451.93B +16.3%
Net Income	151.06B +4.9%
EPS	13,744.90 +7.2%
Shares Out	10.80M
PE Ratio	17.61
Forward PE	19.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,764
Open	230,000
Previous Close	228,000
Day's Range	230,000 - 252,500
52-Week Range	208,500 - 392,000
Beta	0.50
Analysts	Strong Buy
Price Target	357,000.00 (+47.52%)
Earnings Date	Aug 6, 2026

About Hugel

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 594
• Stock Exchange: KOSDAQ
• Ticker Symbol: 145020

Financial Performance

In 2025, Hugel's revenue was 425.11 billion, an increase of 13.96% compared to the previous year's 373.05 billion. Earnings were 140.87 billion, an increase of 3.72%.

Analyst Summary

According to 14 analysts, the average rating for 145020 stock is "Strong Buy." The 12-month stock price target is ₩357,000, which is an increase of 47.52% from the latest price.

Price Target

₩357,000

(47.52% upside)

Analyst Consensus: Strong Buy